Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib

被引：0
作者：
Katsuhiro Masago
Yosuke Togashi
Shiro Fujita
Yuichi Sakamori
Chiyuki Okuda
Young Hak Kim
Tadashi Mio
Michiaki Mishima
机构：
[1] Graduate School of Medicine,Department of Respiratory Medicine
[2] Kyoto University,Division of Integrated Oncology
[3] Institute of Biomedical Research and Innovation,undefined
来源：
Medical Oncology | 2012年 / 29卷
关键词：
Epidermal growth factor receptor; Gefitinib; Hepatocyte growth factor; Non-small cell lung cancer; Somatic mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
A study of patients with advanced non-squamous non-small cell lung cancer (NSCLC) evaluated epidermal growth factor receptor (EGFR) mutation status and serum hepatocyte growth factor (HGF) for their associations with response to gefitinib therapy and prognostic impact. An enzyme-linked immunosorbent assay was used to determine levels of HGF in serum from 96 Japanese patients with advanced non-squamous NSCLC. The peptic nucleic acid-locked nucleic acid clamp method was used to determine their EGFR somatic mutation status. We evaluated the relationship between each independent clinicopathological variable and the response to gefitinib therapy and risk factors associated with prognosis. HGF-positive serum status (hazard ratio, 1.536; 95% confidence interval, 1.042–2.400; P = 0.0295) had a significant and independent negative effect on progression-free survival among patients with wild-type EGFR. We demonstrate that having HGF-positive serum is predictive of a negative response to gefitinib therapy in patients with advanced NSCLC who harbor wild-type EGFR.
引用
收藏
页码：1614 / 1621
页数：7
相关论文
共 356 条
[21]  
Wu YC(2008)Drug development of MET inhibitors: targeting oncogene addiction and expedience Nat Rev Drug Discov 7 504-516
[22]  
Chen YR(1997)Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells Oncogene 14 2417-2423
[23]  
Tsai SF(2009)Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis Cancer Res 69 253-261
[24]  
Shigematsu H(2009)PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription Lab Invest 89 301-314
[25]  
Lin L(2008)Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations Cancer Res 68 9479-9487
[26]  
Takahashi T(2010)TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived hgf in non-small cell lung cancer with an EGFR mutation Mol Cancer Ther 9 2785-:2792
[27]  
Nomura M(2010)Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma Clin Cancer Res 16 4616-4624
[28]  
Suzuki M(1997)Serum hepatocyte growth factor/scatter factor levels in small cell lung cancer patients Lung Cancer 17 211-218
[29]  
Wistuba II(2008)Serum concentration of hepatocyte growth factor (HGF) in oral squamous cell carcinoma before and after surgery. Preliminary report Endokrynol Pol 59 467-470
[30]  
Fong KM(2009)Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients Int J Cancer 125 1657-1662
12345678910